Cagrilintide for Heart Health: What the Evidence Shows
What human and animal studies show about Cagrilintide for heart health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 1
- with an outcome for heart health, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- None found
- with an outcome for heart health, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 2
- with an outcome for heart health
Evidence for heart health
Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| QTc interval | No clinically relevant QTcF prolongation after the last 4.5 mg dose; upper 90% confidence limits of the placebo-adjusted change were below 10 ms. | Human RCTn = 105 | Diabetes, obesity & metabolism 2024, PMID 39279639 |
| Body weight with cagrilintide monotherapy | Cagrilintide monotherapy reduced body weight by a mean difference of -6.08% (-5.89 kg) and also reduced blood pressure, without meaningful HbA1c improvement. | Meta-analysisn = 5425 | Annals of medicine and surgery 2026, PMID 42583410 |
Cagrilintide and heart health are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What heart disease means
MedlinePlus defines heart disease as a general term for many types of heart problems, and a form of cardiovascular disease.[3]
The closest things cagrilintide studies measured
The dose-finding trial registered total cholesterol as one of its outcomes, measured between week 0 and week 26.[4]
Two phase 3 records listed under cagrilintide, one in people with obesity and one with obesity plus type 2 diabetes, register triglycerides as an outcome over 64 weeks. They had not reported when the records were cached.[5]
The obesity-plus-diabetes phase 3 record words its lipid outcome as a triglyceride ratio to baseline over the same 64 weeks.[6]
A pooled analysis of randomised trials reports blood pressure reductions with cagrilintide alone, alongside weight loss.[2]
Cardiac safety data
A dedicated thorough QT study randomised 105 healthy participants to cagrilintide or placebo.[1]
In that QT study the upper limits of the confidence intervals stayed below 10 ms at every time point.[1]
The authors of that QT study state their reading of the result as no increased risk of ventricular tachyarrhythmias.[1]
Other peptides people research for heart health
All peptides for heart health, comparedCommon questions
Does Cagrilintide help with heart health?
The strongest study we summarise for heart health is human rct evidence, across 2 studies with an outcome for heart health. A trial result is not an approval; see the legal status.
Is Cagrilintide approved for heart health?
No. Cagrilintide is not FDA approved for any use, including heart health.
What is the best peptide for heart health?
There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.
Does cagrilintide affect the heart?
The only cardiac-specific study cited is a QT study in healthy volunteers, which found no clinically relevant QTcF prolongation; it did not test heart disease patients.[1]
More on Cagrilintide
Sources
- 1Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
- 2Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
- 3Official web pageOfficial web page · web page
- 4Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial.ClinicalTrials.gov (U.S. National Library of Medicine) · 2019clinicaltrials.govAccessed 2 Oct 2026
- 5Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
- 6Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2025clinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.